The ARMANI study aims to test the hypothesis that anatomic resection (AR) compared to non-anatomic resection (NAR) of liver metastases prolongs intrahepatic disease-free survival of patients with RAS mutated CRLM. The study will be conducted at 20 centers in Germany with high caseloads for hepatobiliary surgery. A total of 240 patients will be enrolled and randomized to AR versus NAR in a 1:1 ratio.
